A first-in-human study of MSB-2311

Trial Profile

A first-in-human study of MSB-2311

Planning
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs MSB 2311 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 25 Oct 2017 According to a MabSpace Biosciences media release, company filed an IND application to CFDA on September 12th, 2017 for MSB2311 and plans to file US IND in December 2017 and start an FIH trial in the US and subsequently in China in the first half of 2018.
    • 07 Mar 2017 New trial record
    • 23 Feb 2017 According to a MabSpace Biosciences media release, the company is planning to start this study later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top